ASH 2021: ZUMA-7 Reveals Benefits of Axicabtagene Ciloleucel in Relapsed/Refractory Large B-Cell Lymphoma
The treatment outperformed standard of care when used after chemoimmunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.